NeuroAudit
Neuromodulation Protocols for Personalized Brain Disease Treatment
Company Overview
Snapshot
Founded in February 2016 by Dan Anzyo, NeuroAudit operates with 1–10 employees. The company has raised $200,000 across one funding round and was recognized in April 2022 as the "Most Innovative Neurotechnology Company in the Middle East" at the Biotechnology Awards.
Business overview
NeuroAudit develops neuro-stimulus neurotechnology focused on treating brain disorders such as Alzheimer's disease and other cognitive conditions. Its core product is a cognitive boost patch that uses a unique algorithm to transmit a non-invasive, pure signal via blood conduction directly to the brain. The company continuously monitors brain states, analyzes data, and controls brain stimulation in real time to enhance understanding of neurological impacts. NeuroAudit's technology has demonstrated improvements in cognitive operations and the ability to transmit sound to deaf individuals through blood conduction, operating within the Health Tech & Life Sciences sector, specifically targeting medical devices and medical treatment & therapeutics.
Strategic signal
In April 2022, NeuroAudit received the "Most Innovative Neurotechnology Company in the Middle East" award at the Biotechnology Awards. This recognition highlights the company's pioneering work in neuro-stimulus technology and signals strong validation of its innovative approach to addressing complex neurological disorders, positioning it as a key player in the regional health tech landscape.
Log in to access full profile ›Company Intelligence Q&A
- When was NeuroAudit founded and by whom?
- NeuroAudit was founded in February 2016 by Dan Anzyo.
- What is NeuroAudit's primary focus in neurotechnology?
- NeuroAudit focuses on developing neuromodulation protocols for personalized brain disease treatment, specifically targeting conditions like Alzheimer's disease and cognitive disorders using a non-invasive cognitive boost patch.
- What was a significant recognition NeuroAudit received?
- In April 2022, NeuroAudit was recognized as the "Most Innovative Neurotechnology Company in the Middle East" at the Biotechnology Awards.
- How much capital has NeuroAudit raised to date?
- NeuroAudit has raised $200,000 across one funding round.
- What is the core mechanism of NeuroAudit's cognitive boost patch?
- The cognitive boost patch transmits a non-invasive, pure signal through a patch attached to the skin, utilizing blood conduction and a unique algorithm to stimulate the brain.